Turcotte EA, Kim K, Eislmayr KD, et al. OspF blocks rapid p38-dependent priming of the NAIP-NLRC4 inflammasome. bioRxiv : the preprint server for biology. 2025. doi:10.1101/2025.02.01.636075
Publications
Park JM, Tsai LH. Innovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease. PLoS biology. 2025;23(2):e3003046. doi:10.1371/journal.pbio.3003046
Chaturantabut S, Oliver S, Frederick DT, et al. Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma. The Journal of clinical investigation. 2025. doi:10.1172/JCI182417
Zhao M, Ryall S, Brody SJ, et al. Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies. Blood advances. 2025;9(5):1003-1012. doi:10.1182/bloodadvances.2024013800
Faure G, Saito M, Wilkinson ME, et al. TIGR-Tas: A family of modular RNA-guided DNA-targeting systems in prokaryotes and their viruses. Science (New York, N.Y.). 2025:eadv9789. doi:10.1126/science.adv9789
Kivimaki M, Frank P, Pentti J, et al. Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the Whitehall II observational cohort study. The Lancet. Digital health. 2025;7(3):e195-e204. doi:10.1016/j.landig.2025.01.006
Papadopoulou A, Litkowski EM, Graff M, et al. Insights from the largest diverse ancestry sex-specific disease map for genetically predicted height. NPJ genomic medicine. 2025;10(1):14. doi:10.1038/s41525-025-00464-w
Tagore S, Caprio L, Amin AD, et al. Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases. Nature medicine. 2025. doi:10.1038/s41591-025-03530-z
Johnson EC, Lai D, Miller AP, et al. Multi-ancestral genome-wide association study of clinically defined nicotine dependence reveals strong genetic correlations with other substance use disorders and health-related traits. medRxiv : the preprint server for health sciences. 2025. doi:10.1101/2025.01.29.25320962
Ruiz-Torres DA, Merkin RD, Bryan M, et al. Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer. medRxiv : the preprint server for health sciences. 2025. doi:10.1101/2025.01.27.25321198